References
- Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 2002;81:139–53.
- Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, Medsger TA Jr, Lucas M, Michet CJ, Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005;118:2–10.
- Henness S, Wigley FM. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review. Curr Opin Rheumatol 2007;19:611–18.
- Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, Goldin J, Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 2008;177:91–8.
- Mittoo S, Wigley FM, Wise R, Xiao H, Hummers L. Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease. Arthritis Rheum 2007;56:4195–202.
- Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655–66.
- White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000;132:947–54.
- Várai G, Earle L, Jimenez SA, Steiner RM, Varga J. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol 1998;25:1325–9.
- Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P, Conforti ML, Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002;29:731–6.
- Kowal-Bielecka O, Kowal K, Rojewska J, Bodzenta-Lukaszyk A, Siergiejko Z, Sierakowska M, Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations. Ann Rheum Dis 2005;64:1343–6.
- Behr J, Vogelmeier C, Beinert T, Meurer M, Krombach F, Konig G, Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med 1996;154:400–6.
- Witt C, Borges AC, John M, Fietze I, Baumann G, Krause A. Pulmonary involvement in diffuse cutaneous systemic sclerosis: broncheoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis 1999;58:635–40.
- Goh NS, Veeraraghavan S, Desai SR, Cramer D, Hansell DM, Denton CP, Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 2007;56:2005–12.
- Clements PJ, Goldin JG, Kleerup EC, Furst DE, Elashoff RM, Tashkin DP, Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis. Arthritis Rheum 2004;50:1909–17.
- Baughman RP, Raghu G. Bronchoalveolar cellular analysis in scleroderma lung disease: does Sutton's law hold? Am J Respir Crit Care Med 2008;177:2–3.
- Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Resp Crit Care Med 2007;76:1026–34.
- Kowal-Bielecka O, Kowal K, Highland KB, Silver RM. Bronchoalveolar lavage fluid in scleroderma interstitial lung disease: technical aspects and clinical correlations: review of the literature. Semin Arthritis Rheum 2009; (Epub ahead of print doi:10.1016/j.semarthrit.2008.10.009).